Telehealth is regulated where the patient is, not where you are. Advertising nationwide availability tells every state board in the country that you are treating their residents.
2026-08-01
FDA wrote to energy-device manufacturers saying it could not identify any clearance for the uses being marketed. What that means for your service page, and why the clearance — not the wording — is the issue.
2026-08-01
A membership that bills automatically is a negative-option offer. Three requirements, where practices fail them, and why the regulator here is your state's consumer-protection office.
2026-08-01
"Repairs DNA," "reverses cellular aging," "lowers your biological age" — the vocabulary that justifies an $800 infusion is structure/function language. How to keep the service and fix the copy.
2026-08-01
Growth-factor products applied after microneedling or laser sit outside the cosmetic lane for two independent reasons — the claims, and the route. What to change on your menu and your aftercare sheet.
2026-08-01
Physicians may prescribe approved drugs off-label — that part is settled. But "off-label" is not a defense for exosomes, peptides, or compounded gels, and it is never a defense for what you advertise.
2026-08-01
BPC-157, TB-500, MOTS-c and LL-37 can't lawfully be compounded under section 503A — and FDA's advisory committee took them up again in July 2026. What that means for your public menu.
2026-07-31
We reviewed the same practice's marketing three ways — keyword screening said 96/100, AI deep analysis said 55, and a full multi-channel audit said Grade D. Here's why the difference matters to your practice.
2026-07-21
Topical exosome and extracellular-vesicle products can be marketed legally — but FDA classifies by the claim you make, not the ingredient you use. Here is where the line sits, and the two ways practices cross it without noticing.
2026-07-21
B&A galleries sell aesthetic services better than anything else — and generate more citations than almost anything else. The FTC, HIPAA, and state board rules in plain English.
2026-07-20
The FDA regulates regenerative products as biologics — and marketing them for structural repair is the fastest way onto its enforcement list. What the rules actually say.
2026-07-20
Why compounded semaglutide marketing is under FDA and FTC scrutiny, the exact phrases to remove, and what compliant weight-loss marketing looks like.
2026-07-20
Guarantees, superlatives, and painless-promises feel like normal marketing — until a medical board reads them. The advertising-conduct rules most practices don't know they're breaking.
2026-07-20
A practical self-audit checklist covering the FDA, FTC, and state board marketing rules that Ohio, Pennsylvania, and West Virginia practices get cited for most.
2026-07-20
"Cures hangovers." "Boosts immunity." "Detoxifies." Why the most common IV lounge marketing phrases turn a wellness service into an unapproved drug — and what to say instead.
2026-07-20